← Leaderboards
Marc H Weiner
University Of Texas Hlth Sci Ctr San Ant
$2,847,341
Attributed
$2,847,341
Total exposure
30
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $237.5K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$2,847,341 · 30
By mechanism
M01$2,847,341 · 30
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr San Ant
Same institution · by research overlap
- Robin Jean Leach$4,298,894
- Ian M Thompson$52,633,085
Others in their field
Top investigators on “Tuberculosis”
- Judith S. Currier · University Of California Los Angeles$301,722,065
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$297,204,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$267,912,117
- Lawrence Corey · Fred Hutchinson Cancer Center$255,939,398
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$200,192,298
- Sharon A Nachman · Johns Hopkins University$194,852,226
Research focus
TuberculosisClinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationIsoniazidRifabutinAntitubercular AgentsRifamycinsHiv InfectionsClinical Trial Phase IMedical ComplicationPharmacokineticsCombination ChemotherapyClinical TrialsFundingGrantResourcesResearch PersonnelDrug InteractionsComputer Retrieval Of Information On Scientific Projects DatabaseDrug Administration Rate /DurationEnrollmentInstitution
Grant awards (57)
CLINICAL TRIAL: RIFAPENTINE/ISONIAZID FOR 3 MONTHS VS 9 MO FOR LATENT TB (STUDY$13,457
M01 · FY2008 · RR · contact PI
CLINICAL TRIAL: EVAL OF A MOXIFLOXACIN-BASED REGIMEN FOR TB TREATMENT, STUDY 28$2,958
M01 · FY2008 · RR · contact PI
PHARMACOKINETIC ISSUES IN THE USE OF MOXIFLOXACIN FOR TREATMENT OF TUBERCULOSIS$694
M01 · FY2008 · RR · contact PI
A PILOT STUDY TO EVALUATE NUCLEIC ACID AMPLIFICATION TESTS TO PREDICT TB RELAPSE$232
M01 · FY2008 · RR · contact PI
STUDY 26PK, RIFAPENTINE PKS IN CHILDREN RECEIVING WEEKLY ISONIAZID FOR TB (HIV)$148
M01 · FY2008 · RR · contact PI
RIFAPENDINE/ISONIAZID FOR 3 MONTHS VS 9 MO FOR LATENT TB (STUDY 26) (HIV)$92,037
M01 · FY2007 · RR · contact PI
EVAL OF A MOXIFLOXACIN-BASED REGIMEN FOR TB TREATMENT, STUDY 28 (HIV)$58,691
M01 · FY2007 · RR · contact PI
PHARMACOKINETIC ISSUES IN THE USE OF MOXIFLOXACIN FOR TREATMENT OF TUBERCULOSIS$41,559
M01 · FY2007 · RR · contact PI
CLINICAL ASSESSMENT OF HYPERSENSITIVITY TO ISONIAZID AND RIFAPENTINE IN STUDY 26$9,143
M01 · FY2007 · RR · contact PI
AN EVAL OF ACTIVITY AND TOLERABILITY OF MOXIFLOXACIN IN TX FOR TB-STUDY 27 (HIV)$8,003
M01 · FY2007 · RR · contact PI
A PILOT STUDY TO EVALUATE NUCLEIC ACID AMPLIFICATION TESTS TO PREDICT TB RELAPSE$7,896
M01 · FY2007 · RR · contact PI
IMPACT OF CHRONIC VIRAL HEPATITIS ON PT D/C OF TX FOR LATENT TB-STUDY 26A (HIV)$5,335
M01 · FY2007 · RR · contact PI
RIFAPENDINE/ISONIAZID FOR 3 MONTHS VS 9 MO FOR LATENT TB (STUDY 26) (HIV)$57,491
M01 · FY2006 · RR · contact PI
PHARMACOKINETIC ISSUES IN THE USE OF MOXIFLOXACIN FOR TREATMENT OF TUBERCULOSIS$32,111
M01 · FY2006 · RR · contact PI
AN EVAL OF ACTIVITY/TOLERABILITY OF MOXIFLOXACIN DURING TX FOR TB-STUDY 27 (HIV)$22,358
M01 · FY2006 · RR · contact PI
A PILOT STUDY TO EVALUATE NUCLEIC ACID AMPLIFICATION TESTS TO PREDICT TB RELAPSE$18,286
M01 · FY2006 · RR · contact PI
CLINICAL ASSESSMENT OF HYPERSENSITIVITY TO ISONIAZID AND RIFAPENTINE IN STUDY 26$8,028
M01 · FY2006 · RR · contact PI
EVALUATION OF A MOXIFLOXACIN-BASED REGIMEN FOR TB TREATMENT, STUDY 28$1,064
M01 · FY2006 · RR · contact PI
AN EVAL OF ACTIVITY AND TOLERABILITY OF MOXIFLOXACIN DURING TX FOR TB - STUDY 27$81,473
M01 · FY2005 · RR
RIFAPENDINE/ISONIAZID FOR 3 MONTHS VS 9 MO FOR LATENT TB (STUDY 26)$75,887
M01 · FY2005 · RR
A PILOT STUDY TO EVALUATE NUCLEIC ACID AMPLIFICATION TESTS TO PREDICT TB RELAPSE$44,091
M01 · FY2005 · RR
PHARMACOKINETIC ISSUES IN THE USE OF MOXIFLOXACIN FOR TREATMENT OF TUBERCULOSIS$34,027
M01 · FY2005 · RR
IMPACT OF CHRONIC VIRAL HEPATITIS ON PT D/C OF TX FOR LATENT TB-STUDY 26A$2,025
M01 · FY2005 · RR
RIFAPENTINE/ISONIAZID FOR 3 VS 9 MONTHS FOR TB$50,961
M01 · FY2004 · RR
ACTIVITY/TOLERABILITY OF MOXIFLOXACIN DURING TB THERAPY$6,145
M01 · FY2004 · RR
Nucleic Acid Amplification Tests to Predict TB Relapse$3,976
M01 · FY2004 · RR
PHARMACOKINETICS OF RIFAPENTINE DURING THERAPY OF TB$3,253
M01 · FY2004 · RR
THERAPY OF HIV-RELATED TB USING RIFABUTIN-BASED REGIMEN$1,807
M01 · FY2004 · RR
VIRAL HEPATITIS THERAPY--IMPACT ON TB &HEPATOTOXICITY$1,445
M01 · FY2004 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS$234,837
M01 · FY2002 · RR
DRUG PHARMACOKINETICS &RISK FACTORS FOR RELAPSE IN RIFAPENTINE TRIAL$234,837
M01 · FY2002 · RR
DRUG PHARMACOKINETICS &RISK FACTORS FOR RELAPSE IN RIFAPENTINE TRIAL$234,837
M01 · FY2002 · RR
SERUM BANKING FOR EVALUATION OF NEW DIAGNOSTIC AND TREATMENT TECHNOLOGY FOR TB$234,837
M01 · FY2002 · RR
SERUM BANKING FOR EVALUATION OF NEW DIAGNOSTIC AND TREATMENT TECHNOLOGY FOR TB$234,837
M01 · FY2002 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS$234,837
M01 · FY2002 · RR
PHARMACOKINETICS OF ISONIAZID AND RIFABUTIN IN HIV TB$0
M01 · FY2002 · RR
THERAPY OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2002 · RR
THERAPY OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2002 · RR
PHARMACOKINETICS--RIFABUTIN/REVERSE TRANSCRIPTASE INHIBI$0
M01 · FY2002 · RR
PHARMACOKINETICS--RIFABUTIN/REVERSE TRANSCRIPTASE INHIBI$0
M01 · FY2002 · RR
HIGH DOSAGE RIFAPENTINE IN THERAPY OF TB IN NORMAL PTS$0
M01 · FY2002 · RR
HIGH DOSAGE RIFAPENTINE IN THERAPY OF TB IN NORMAL PTS$0
M01 · FY2002 · RR
PHARMACOKINETICS OF ISONIAZID AND RIFABUTIN IN HIV TB$0
M01 · FY2002 · RR
SERUM BANKING FOR EVALUATION OF NEW DIAGNOSTIC AND TREATMENT TECHNOLOGY FOR TB$234,837
M01 · FY2001 · RR
DRUG PHARMACOKINETICS &RISK FACTORS FOR RELAPSE IN RIFAPENTINE TRIAL$234,837
M01 · FY2001 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS$234,837
M01 · FY2001 · RR
PHARMACOKINETICS OF ISONIAZID AND RIFABUTIN IN HIV TB$0
M01 · FY2001 · RR
THERAPY OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2001 · RR
PHARMACOKINETICS--RIFABUTIN/REVERSE TRANSCRIPTASE INHIBI$0
M01 · FY2001 · RR
HIGH DOSAGE RIFAPENTINE IN THERAPY OF TB IN NORMAL PTS$0
M01 · FY2001 · RR
SERUM BANKING FOR EVALUATION OF NEW DIAGNOSTIC AND TREATMENT TECHNOLOGY FOR TB$16,409
M01 · FY2000 · RR
DRUG PHARMACOKINETICS &RISK FACTORS FOR RELAPSE IN RIFAPENTINE TRIAL$16,409
M01 · FY2000 · RR
EFFICACY OF RIFAPENTINE AND INH AS THERAPY FOR PULMONARY TUBERCULOSIS$16,409
M01 · FY2000 · RR
PHARMACOKINETICS OF ISONIAZID AND RIFABUTIN IN HIV TB$0
M01 · FY2000 · RR
THERAPY OF HIV RELATED TUBERCULOSIS USING RIFABUTIN$0
M01 · FY2000 · RR
PHARMACOKINETICS--RIFABUTIN/REVERSE TRANSCRIPTASE INHIBI$0
M01 · FY2000 · RR
HIGH DOSAGE RIFAPENTINE IN THERAPY OF TB IN NORMAL PTS$0
M01 · FY2000 · RR